BridgeBio Pharma, Inc. (BBIO) Form 8-K — Oct 29, 2026
BridgeBio Pharma reported Q3 2026 total revenues of $353.2 million, up from $120.7 million a year ago, led by $253.2 million in U.S. Attruby net product revenue (+~$145 million YoY) plus a one-time $75.0 million Bayer sales milestone. Loss from operations narrowed sharply to $11.6 million and net loss attributable to common stockholders was $83.0 million, or $0.42 per share, versus $0.95 a year earlier. The company holds $1.5 billion in cash, cash equivalents and marketable securities, which it says fully funds all three launches and expansion indications.
Key figures
- Revenue
- 353171000
- Revenue Yoy
- +$232.5 million (from $120.7M to $353.2M)
- Cash Position
- 1538855000
- Pdufa dates
- ["BBP-418 (LGMD2I/R9): November 27, 2026","infigratinib (achondroplasia): February 4, 2027","encaleret (ADH1): May 8, 2027"]
- Cash dec 31 2025
- 587482000
- Attruby seq growth
- +~$31 million sequentially, +$145 million YoY
- Royalty revenue q3
- 20511000
- Bayer sales milestone
- 75000000
- License services revenue q3
- 79314000
- Attruby us net revenue q3 2026
- 253200000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.